Standout Papers

A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disea... 1997 2026 2006 2016 1.7k
  1. A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease (1997)
    Mary Sano, Christopher Ernesto et al. New England Journal of Medicine
  2. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment (2005)
    Ronald Petersen, Ronald G. Thomas et al. New England Journal of Medicine
  3. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease (1997)
    Douglas Galasko, David A. Bennett et al. Alzheimer Disease & Associated Disorders
  4. Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials (2004)
    Michael Grundman Archives of Neurology
  5. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. (2003)
    Paul Aisen, Kimberly Schafer et al. PubMed
  6. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. (2000)
    Ruth A. Mulnard, Carl W. Cotman et al. PubMed
  7. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study (2010)
    Juha O. Rinne, David J. Brooks et al. The Lancet Neurology
  8. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup (2011)
    Reisa A. Sperling, Clifford R. Jack et al. Alzheimer s & Dementia
  9. Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change (1997)
    Lara Schneider, Jason T. Olin et al. Alzheimer Disease & Associated Disorders
  10. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease (2020)
    Martí Colom‐Cadena, Tara L. Spires‐Jones et al. Alzheimer s Research & Therapy

Immediate Impact

5 from Science/Nature 123 standout
Sub-graph 1 of 14

Citing Papers

Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
2023 Standout
Alzheimer's disease: From immunotherapy to immunoprevention
2023 Standout
88 intermediate papers

Works of Michael Grundman being referenced

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
2012
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
2011 Standout
and 30 more

Author Peers

Author Last Decade Papers Cites
Michael Grundman 6820 5786 1906 2564 115 14.4k
Ronald G. Thomas 7593 5459 2637 2923 175 18.2k
Stephen Salloway 5726 4848 1939 2029 172 13.1k
Eric Siemers 6875 4187 2495 2022 165 11.3k
L. J. Thal 5964 5738 2179 2170 116 13.5k
Pierre N. Tariot 4985 7505 1765 3842 279 14.5k
John C.S. Breitner 7939 8961 2379 1919 270 20.2k
Paul Aisen 7982 7991 2239 1727 269 16.4k
Gordon Wilcock 5533 4197 2803 2538 223 14.3k
Lon S. Schneider 3605 7402 1312 2999 263 14.5k
Rachelle S. Doody 8341 9992 2516 4213 240 20.7k

All Works

Loading papers...

Rankless by CCL
2026